Drug Trial Radar · NCT06247735
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Feb 7, 2024
Primary completion
Jun 26, 2025
Study completion Jul 23, 2026
Sponsor
- Lead sponsor
- Kowa Research Institute, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Conditions
- Primary Biliary Cholangitis
Interventions
K-808 (Dose A)Drug
Administered orally once daily
K-808 (Dose B)Drug
Administered orally once daily
PlaceboDrug
Administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in serum alkaline phosphatase (ALP)Time frame: Baseline to Week 12
Locations
38 sites in 3 countries. Site status is shown where the registry gives one.
UA Thomas D. Boyer Liver Institute
Tucson, Arizona
Southern California Research Center - Coronado
Coronado, California
Cedars-Sinai Medical Center
Los Angeles, California
Velocity Clinical Research
Santa Ana, California
Peak Gastroenterology Associates Colorado Springs
Colorado Springs, Colorado
University of Florida Hepatology Research at CTRB
Gainesville, Florida
Florida Research Institute
Lakewood Rch, Florida
University of Miami Leonard M. Miller School of Medicine
Miami, Florida
Springfield Clinic
Springfield, Illinois
Mercy Medical Center - Mcauley Plaza
Baltimore, Maryland
CommonSpirit Health Research Institute
Omaha, Nebraska
New York University Hepatology Associates
New York, New York
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Einstein Medical Center
Philadelphia, Pennsylvania
Rapid City Medical Center
Rapid City, South Dakota
Vanderbilt Digestive Disease Center
Nashville, Tennessee
Pioneer Research Solutions
Houston, Texas
UVA Health - University of Virginia Health System
Charlottesville, Virginia
Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists
Norfolk, Virginia
Liver Institute Northwest
Seattle, Washington
(G.I,R,I) GI Research Institute
Vancouver, British Columbia, Canada
Office of Dr. Gauthier
North Bay, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM)
Montreal, Quebec, Canada
306
Fukui, Japan
313
Fukuoka, Japan
305
Hamamatsu, Japan
308
Hirakata, Japan
309
Hiroshima, Japan
304
Isehara, Japan
312
Kanazawa, Japan
307
Matsumoto, Japan
311
Ōmura, Japan
302
Sapporo, Japan
Teine Keijinkai Hospital
Sapporo, Japan
303
tabashi City, Japan
314
Yokohama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.